Camozzi joins AMT on 18 July from Orphan Europe, where he held the position of medical director for more than five years. Prior to this, he was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities.
From 2001–2005, Camozzi was md of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programmes for pharmaceutical and healthcare products.
Dr Camozzi started his career in South America holding roles at Lederle/American Cyanamid and F Hoffmann La-Roche.
Amsterdam Molecular Therapeutics appoints chief medical officer
Dutch human gene therapy specialist hires Carlos Camozzi
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Sustainability
PFAS regulation pressure intensifies as new Chemspec whitepaper urges early industry action
A new whitepaper launched at Chemspec Europe 2026 warns that tightening global PFAS regulation could trigger major supply chain and compliance challenges for chemical manufacturers unless companies begin transition planning now
Research & Development
Concept Life Science and OpenBench team up on AI-driven hit discovery platform for biotechs
The pair will combine AI-powered virtual screening, medicinal chemistry and in-vitro validation in a fee-for-success model designed to accelerate hit identification and reduce early-stage drug discovery risk for biotech firms
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027